flurbiprofen farmak
farmak international sp. z o.o. - flurbiprofenas - burnos gleivinės purškalas (tirpalas) - 8,75 mg/dozėje - flurbiprofen
rivaroxaban farmak
farmak international sp. z o.o. - rivaroksabanas - plėvele dengtos tabletės - 2,5 mg - rivaroxaban
rivaroxaban farmak
farmak international sp. z o.o. - rivaroksabanas - plėvele dengtos tabletės - 10 mg - rivaroxaban
rivaroxaban farmak
farmak international sp. z o.o. - rivaroksabanas - plėvele dengtos tabletės - 15 mg - rivaroxaban
rivaroxaban farmak
farmak international sp. z o.o. - rivaroksabanas - plėvele dengtos tabletės - 20 mg - rivaroxaban
benzydamine hydrochloride/cetylpyridinium chloride farmak
farmak international sp. z o.o. - benzidamino hidrochloridas/cetilpiridinio chloridas - burnos gleivinės purškalas (tirpalas) - 1,5 mg/5 mg/ml - various
azacitidine icg farma
icg farma, uab - azacitidinas - milteliai injekcinei suspensijai - 25 mg/ml - azacitidine
iohexol icg farma
icg farma, uab - joheksolis - injekcinis tirpalas - 647 mg/ml - iohexol
iohexol icg farma
icg farma, uab - joheksolis - injekcinis tirpalas - 755 mg/ml - iohexol
menquadfi
sanofi pasteur - neisseria meningitidis group c polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group a polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group y polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group w-135 polysaccharide conjugated to tetanus toxoid - meningitas, meningokokas - vakcinos - menquadfi is indicated for active immunisation of individuals from the age of 12 months and older against invasive meningococcal disease caused by neisseria meningitidis serogroups a, c, w, and y. the use of this vaccine should be in accordance with available official recommendations.